Zobrazeno 1 - 10
of 92
pro vyhledávání: '"D. R. Gandara"'
Publikováno v:
MD Conference Express. 15:2-4
Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials
Autor:
Silvana Martino, Charles A. Coltman, Kathy S. Albain, Laura F. Hutchins, D. R. Gandara, Joseph M. Unger, Robert B. Livingston, John S. Macdonald, E. David Crawford, John Crowley, Charles D. Blanke
Publikováno v:
Journal of Clinical Oncology. 24:141-144
Purpose A prior analysis by the Southwest Oncology Group (SWOG) showed that women and African American patients were adequately represented on cancer clinical treatment trials but that older patients were substantially underrepresented. Twenty-five p
Autor:
C M, Moinpour, B, Lyons, P K, Grevstad, L C, Lovato, J, Crowley, K, Czaplicki, Z M, Buckner, P A, Ganz, K, Kelly, D R, Gandara
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 11(2)
The main purpose of this paper is to present the results of a randomized trial comparing the effects of two chemotherapy regimens on the Quality of life (QOL) of patients with advanced non-small-cell lung cancer (NSCLC). Trials in advanced stage dise
Autor:
K, Kelly, L, Lovato, P A, Bunn, R B, Livingston, J, Zangmeister, S A, Taylor, D, Roychowdhury, J J, Crowley, D R, Gandara
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
This study was designed to determine the efficacy and toxicity of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive-stage small cell lung cancer (ES-SCLC).Chemo-naive adult patients with a performance status (PS) of 0-2 and adequa
Publikováno v:
Cancer. 92(1)
The objective of this Phase II study was to evaluate the concept of sequential chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC) by the administration of carboplatin plus gemcitabine followed by of paclitaxe
Publikováno v:
Seminars in oncology. 28(3 Suppl 9)
Randomized clinical trials have shown that combinations of chemotherapy plus thoracic radiation improve survival compared with radiotherapy alone in stage III non--small cell lung cancer (NSCLC). Furthermore, two recent studies have concluded that co
Publikováno v:
Anti-cancer drugs. 12
Clinical trials evaluating neoadjuvant or preoperative therapy for locally advanced non-small cell lung cancer (NSCLC) have demonstrated the feasibility, tolerability and activity of this approach. Three randomized trials have reported improved survi
Publikováno v:
Oncology (Williston Park, N.Y.). 15(3 Suppl 6)
Combinations of gemcitabine (Gemzar) with cisplatin (Platinol) are among the most active new chemotherapy regimens developed for advanced non-small-cell lung cancer. Carboplatin (Paraplatin) is a platinum analog devoid of many of the nonhematologic t
Publikováno v:
Oncology (Williston Park, N.Y.). 14(7 Suppl 5)
A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non-small-cell lung cancer (NSCLC) more effectively
Publikováno v:
Oncology (Williston Park, N.Y.). 14(7 Suppl 4)
Platinum compounds, either cisplatin (Platinol) or carboplatin (Paraplatin), in combination with a number of new chemotherapeutic agents, have demonstrated improved response or survival compared to cisplatin alone or older platinum-based regimens. Ge